Literature DB >> 10640519

Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat.

F Le Doze1, D Debruyne, F Albessard, L Barre, G L Defer.   

Abstract

We have measured the pharmacokinetics of three retinoids, all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in rat blood and rat brain [especially white matter (WM) and gray matter (GM)] to help select retinoids for treating human malignant glioma. All-trans retinoic acid permeated well into the WM, giving peak concentration in WM of 25.7 microg/g, 6 to 7 times higher than the peak serum concentration. There was less 13-cis retinoic acid in WM: area under the curve (AUC)(0-->infinity) WM/AUC(0-->infinity) serum = 18.00 microg ml(-1) h/32.67 microg ml(-1) h. The ratio WM/GM was over 1 for these two compounds, but the half-lives were short in the serum and cerebral tissue (0.57-1.02 h). Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM). These findings provide information that may be used to select a retinoid and establish therapeutic regimens that provide optimal efficacy with minimal toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640519

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.

Authors:  Hwang Eui Cho; H Kang Min
Journal:  J Pharm Biomed Anal       Date:  2016-09-29       Impact factor: 3.935

2.  Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Authors:  Oliver Grauer; Christina Pascher; Christian Hartmann; Florian Zeman; Michael Weller; Martin Proescholdt; Alexander Brawanski; Thorsten Pietsch; Wolfgang Wick; Ulrich Bogdahn; Peter Hau
Journal:  J Neurooncol       Date:  2011-03-04       Impact factor: 4.130

3.  Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.

Authors:  Vinay K Puduvalli; W K Alfred Yung; Kenneth R Hess; John G Kuhn; Morris D Groves; Victor A Levin; James Zwiebel; Susan M Chang; Timothy F Cloughesy; Larry Junck; Patrick Wen; Frank Lieberman; Charles A Conrad; Mark R Gilbert; Christina A Meyers; Vivien Liu; Minesh P Mehta; M Kelly Nicholas; Michael Prados
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

4.  Inhibitors of EGFR signaling retard cytotoxicity of fenretinide in rat gliosarcoma cells.

Authors:  Ayesha Zaheer; Shailendra K Sahu; Vincent C Traynelis
Journal:  Neurochem Res       Date:  2007-06-19       Impact factor: 3.996

Review 5.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.

Authors:  Hyun-Pil Lee; Gemma Casadesus; Xiongwei Zhu; Hyoung-gon Lee; George Perry; Mark A Smith; Katarzyna Gustaw-Rothenberg; Alan Lerner
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

6.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

7.  A rapid, sensitive and selective liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry method for determination of fenretinide (4-HPR) in plasma.

Authors:  James I Lee; Vu T Nguyen; Mei-Ling Chen; Peter C Adamson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-11-04       Impact factor: 3.205

8.  Administration of all-trans retinoic acid after experimental traumatic brain injury is brain protective.

Authors:  Regina Hummel; Sebastian Ulbrich; Dominik Appel; Shuailong Li; Tobias Hirnet; Sonja Zander; Wieslawa Bobkiewicz; Christina Gölz; Michael K E Schäfer
Journal:  Br J Pharmacol       Date:  2020-10-23       Impact factor: 8.739

9.  Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1.

Authors:  Abhijit M Godbole; Puranik Purushottamachar; Marlena S Martin; Vincent C O Njar
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-13       Impact factor: 3.333

10.  Neural stem cells and cholinergic neurons: regulation by immunolesion and treatment with mitogens, retinoic acid, and nerve growth factor.

Authors:  Laura Calza; Alessandro Giuliani; Mercedes Fernandez; Stefania Pirondi; Giulia D'Intino; Luigi Aloe; Luciana Giardino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.